Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): A phase 3 factorial randomised controlled trial

The Lancet Oncology

Volumn 15, Issue 8, 2014, Pages 886-893

  Tsuburaya, Akira ^a   Yoshida, Kazuhiro ^b   Kobayashi, Michiya ^c   Yoshino, Shigefumi ^d   Takahashi, Masazumi ^e   Takiguchi, Nobuhiro ^f   Tanabe, Kazuaki ^g   Takahashi, Naoto ^h   Imamura, Hiroshi ⁱ   Tatsumoto, Naokuni ^j   Hara, Akinori ^k   Nishikawa, Kazuhiro ^l   Fukushima, Ryoji ^m   Nozaki, Isao ⁿ   Kojima, Hiroshi ^o   Miyashita, Yumi ^p   Oba, Koji ^q   Buyse, Marc ^r   Morita, Satoshi ^s   Sakamoto, Junichi ^t  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KOCHI MEDICAL SCHOOL   (Japan)

^d YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

^f CHIBA CANCER CENTER   (Japan)

^g HIROSHIMA UNIVERSITY   (Japan)

^h JIKEI UNIVERSITY HOSPITAL   (Japan)

ⁱ SAKAI MUNICIPAL HOSPITAL   (Japan)

^j Miyoshi Central Hospital   (Japan)

^k Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

^l Department of Paediatrics   (Japan)

^m TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^o Aichi Hospital   (Japan)

^p NPO Epidemiological and Clinical Research Information Network   (Japan)

^q HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^r INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^s KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^t Tokai Central Hospital of Japan Mutual Aid Association of Public School Teachers   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PACLITAXEL; UFT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER SIZE; CANCER STAGING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DYSPNEA; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPOTENSION; INTENTION TO TREAT ANALYSIS; JAPAN; LEUKOPENIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STOMACH CANCER; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE DISORDER; VOMITING;

ADENOCARCINOMA; AGED; ANOREXIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; OXONIC ACID; PACLITAXEL; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR; URACIL;

EID: 84903527021     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70025-7     Document Type: Article

References (44)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355:11-20.
3. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007, 357:1810-1820.
4. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012, 379:315-321.
5. Oba K, Morita S, Tsuburaya A, Kodera Y, Kobayashi M, Sakamoto J Efficacy of adjuvant chemotherapy using oral fluorinated pyrimidines for curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials in Japan. J Chemother 2006, 18:311-317.
6. Wilson PM, Danenberg PV, Johnston PG, Lenz HJ, Ladner RD Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol 2014, 11:282-298.
7. Jimenez P, Pathak A, Phan AT The role of taxanes in the management of gastroesphageal cancer. J Gastrointest Oncol 2011, 2:240-249.
8. Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012, 379:432-444.
9. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009, 374:1331-1338.
10. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005, 23:5542-5551.
11. Mauri D, Kamposioras K, Tsali L, et al. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: a meta-analysis. Cancer Treat Rev 2010, 36:69-74.
12. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003, 21:1431-1439.
13. Francis P, Crown J, Di Leo A, et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 2008, 100:121-133.
14. Sakamoto J, Matsui T, Kodera Y Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer 2009, 12:69-78.
15. Sun Z, Xu YY, Wang ZN, et al. Macroscopic serosal classification predicts peritoneal recurrence for patients with gastric cancer underwent potentially curative surgery. Ann Surg Oncol 2011, 18:1068-1080.
16. Kobayashi M, Sakamoto J, Namikawa T, et al. Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. World J Gastroenterol 2006, 12:1412-1415.
17. Boku N JCOG trials of systemic chemotherapy for unresectable or recurrent gastric cancer. Gastric Cancer 2009, 12(suppl 1):43-49.
18. Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 2013, 31:4438-4444.
19. Nakajima T, Kinoshita T, Nashimoto A, et al. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 2007, 94:1468-1476.
20. Aoyama T, Yoshikawa T, Shirai J, et al. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer. Ann Surg Oncol 2013, 20:2000-2006.
21. Grem JL, Nguyen D, Monahan BP, Kao V, Geoffroy FJ Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells. Biochem Pharmacol 1999, 58:477-486.
22. Kobayashi M, Tsuburaya A, Nagata N, Miyashita Y, Oba K, Sakamoto J A feasibility study of sequential paclitaxel and S-1 (PTX/S-1) chemotherapy as postoperative adjuvant chemotherapy for advanced gastric cancer. Gastric Cancer 2006, 9:114-119.
23. Biondi A, Hyung WJ Seventh edition of TNM classification for gastric cancer. J Clin Oncol 2011, 29:4338-4339.
24. Tsuburaya A, Sakamoto J, Morita S, et al. A randomized phase III trial of post-operative adjuvant oral fluoropyrimidine versus sequential paclitaxel/oral fluoropyrimidine and UFT versus S1 for T3/T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (Samit) Trial. Jpn J Clin Oncol 2005, 35:672-675.
25. Iwasaki Y, Sasako M, Yamamoto S, et al. Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). J Surg Oncol 2013, 107:741-745.
26. Aoyama T, Yoshikawa T, Watanabe T, et al. Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1. Gastric Cancer 2011, 14:274-278.
27. Japanese Classification of Gastric Carcinoma 2nd Edn. Gastric Cancer 1998, 1:10-24. Japanese Gastric Cancer Association.
28. Nakajima T, Takahashi T, Takagi K, Kuno K, Kajitani T Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J Clin Oncol 1984, 2:1366-1371.
29. Nakajima T, Nashimoto A, Kitamura M, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Lancet 1999, 354:273-277. theGastric Cancer Surgical Study Group.
30. Nashimoto A, Nakajima T, Furukawa H, et al. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosanegative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol 2003, 21:2282-2287. the Gastric Cancer Surgical Study Group, Japan Clinical Oncology GroupJapan Clinical Oncology Group.
31. Fujii M, Sakabe T, Wakabayashi K, et al. The optimal period for orally administered fluoropyrimidines as an adjuvant chemotherapy for gastric cancer: a pilot study using 5-FU tablets compared with surgical operation alone. Gan To Kagaku Ryoho 1994, 21:1199-1208. [in Japanese].
32. Sakamoto J, Tsuburaya A, Morita S, et al. Adjuvant chemotherapy with tegafur/uracil (UFT) for gastric cancer. A meta-analysis of centrally randomized clinical trials. J Clin Oncol 2006, 24(18 suppl):4033.
33. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725-730.
34. Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012, 30:268-273.
35. Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011, 29:4387-4393.
36. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006, 24:2903-2909.
37. Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010, 303:1729-1737.
38. Bickenbach K, Strong VE Comparisons of gastric cancer treatments: east vs. west. J Gastric Cancer 2012, 12:55-62.
39. Kim AR, Cho J, Hsu YJ, et al. Changes of quality of life in gastric cancer patients after curative resection: a longitudinal cohort study in Korea. Ann Surg 2012, 256:1008-1013.
40. Kong H, Kwon OK, Yu W Changes of quality of life after gastric cancer surgery. J Gastric Cancer 2012, 12:194-200.
41. Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Maas HA, Coebergh JW Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol 2005, 55:231-240.
42. Scher KS, Hurria A Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol 2012, 30:2036-2038.
43. Loibl S, von Minckwitz G, Harbeck N, et al. Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials. Breast Cancer Res 2008, 10:R77.
44. Oba K, Paoletti X, Alberts S, et al. Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst 2013, 105:1600-1607.